Results 91 to 100 of about 2,201,777 (199)

Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines [PDF]

, 2020
Background: Osimertinib improve therapy for non-small cell lung cancer (NSCLC). However, invariable acquired resistance appears. Methods: MTT assay was used to analyze cell viability. Protein expression and activation was detected by Western blotting. In
Bracht, Jillian Willhelmina Paulina, Ito, Masaoki, Codony Servat, Carles, Rosell, Rafael, Molina Vila, Miguel Angel, Karachaliou, Niki, Viteri, Santiago, Berenguer, Jordi, Codony Servat, Jordi, Chaib, Imane   +9 more
core   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, Volume 159, Issue 9, Page 2244-2261, 1 November 2026.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report

, 2022
Introduction: EGFR L747P mutations occur rarely, with limited preclinical research and case reports suggesting resistance to osimertinib. Main Concerns, Important Clinical Findings, Primary Diagnoses, Interventions, Outcomes: An 84-year-old white male ...
Gagan, J, Mayer, M, Gerber, DE, von Itzstein, MS   +3 more
core   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

Evaluating the Impact of CYP1A2 Inhibition on the Pharmacokinetics of Savolitinib: A Phase 1 Open‐Label Study

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Savolitinib is an oral, potent, selective CNS‐penetrant MET‐tyrosine kinase inhibitor that in vitro studies indicate is metabolized by cytochrome P450 (CYP) enzymes, including CYP1A2, and by non‐CYP enzymes, such as aldehyde oxidase (AO). Savolitinib primary metabolites, M2 and M3, are formed mainly by CYP1A2 and AO, respectively. This Phase 1,
Kowser Miah, Jitendar Reddy, Pradeep Sharma, Ike Igwegbe, Simon Nelson, Caitlin Muldoon, Ronald Goldwater, Karthick Vishwanathan   +7 more
wiley   +1 more source

Inhibition of BRD4 sensitizes NSCLC cells to osimertinib by suppressing APT1 and promoting MST1 palmitoylation

Cell Death Discovery
Osimertinib is widely used to treat non-small-cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) mutations. However, osimertinib resistance inevitably develops in almost all patients.
Shaoqiang Wang, Yingying Zheng, Zhenyu Zhang, Lijie Qiu, Wolong Zhou, Heng Zhang   +5 more
doaj   +1 more source

Genotype‐directed therapy for non–small cell lung cancer diagnosed during pregnancy: A pooled analysis of seven cases from the Cancer and Pregnancy Registry with maternal and neonatal outcomes and review of the literature

Acta Obstetricia et Gynecologica Scandinavica, Volume 105, Issue 10, Page 2089-2096, October 2026.
In this retrospective case series from a single database of pregnant women with cancer, seven were diagnosed with non‐small cell lung cancer (NSCLC). Chemotherapy and in some cases also biomarker‐directed therapy during pregnancy were associated with disease control allowing delivery closer to term and resulting in improved maternal outcomes compared ...
Reed Firestone, John Gaughan, Elyce Cardonick   +2 more
wiley   +1 more source

Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer

International Journal of Molecular Sciences
Non-small-cell lung cancer (NSCLC) represents the most common type of lung cancer. The majority of patients with lung cancer characterized by activating mutations in the epidermal growth factor receptor (EGFR), benefit from therapies entailing tyrosine kinase inhibitors (TKIs).
Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco   +2 more
openaire   +3 more sources

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source